BioMarin lowers FY26 non-GAAP EPS view to $4.85-$5.05 from $4.95-$5.15

Raises FY26 revenues view to $3.825B-$3.925 from $3.325B-$3.425B. Consensus is for FY26 EPS $4.64 and for revenue $3.83B. Updated guidance reflects post-close contributions from Amicus beginning April 27. As previously communicated, the acquisition of Amicus is expected to be slightly dilutive to FY26 Non-GAAP Diluted EPS; historical BioMarin (BMRN) Non-GAAP Diluted EPS guidance is unchanged. The Amicus acquisition will be accounted for as a business combination, which will result in intangible amortization impacting GAAP results over future periods and excluded from Non-GAAP results. BioMarin will continue to include interest expense related to the Amicus financing in both GAAP and Non-GAAP financial results. Guidance is subject to change based on various factors including finalization of purchase accounting. The company expects approximately two-thirds of 2026 Non-GAAP Diluted EPS to be recognized in the second half of 2026, primarily due to the anticipated timing of revenue. Non-GAAP Diluted EPS in Q2 is expected to be modestly higher than in Q1.